Nymox Pharmaceutical Corporation NYMXF

Company Overview

Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on the research and development of drug therapies, historically targeting urological disorders and central nervous system conditions. The company has operated within the biotechnology and pharmaceutical research industry, with its primary strategic emphasis on developing proprietary drug candidates rather than commercializing approved products. As of the most recent publicly available disclosures, Nymox has not generated material recurring revenue from product sales.

The company’s historical core asset was NX-1207, an injectable drug candidate intended for the treatment of benign prostatic hyperplasia (BPH). Nymox positioned itself as a developer of minimally invasive therapeutic solutions aimed at improving patient outcomes compared to existing surgical or pharmacological alternatives. Founded in 1989, the company evolved from a broader pharmaceutical research entity into a narrowly focused development-stage biotechnology company, though its clinical and regulatory progress has been limited and subject to regulatory scrutiny over time.